SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF AXA1125 AND AXA1957 IN A PROSPECTIVE 16-WEEK RANDOMIZED, PLACEBO-CONTROLLED STUDY IN SUBJECTS WITH NAFLD WITH AND WITHOUT TYPE 2 DIABETES

被引：0
|
作者：
Harrison, Stephen A. [1 ]
Gunn, Nadege T. [2 ]
Baum, Seth J. [3 ]
Younes, Ziad H. [4 ]
Kohli, Anita [5 ]
Patil, Rashmee [6 ]
Koziel, Margaret J. [7 ]
Chera, Harinder [7 ]
Zhao, Jeff [7 ]
Chakravarthy, Manu V. [7 ]
机构：
[1] Pinnacle Clin Res Ctr, San Antonio, TX USA
[2] Pinnacle Clin Res, San Antonio, TX USA
[3] Excel Med Clin Trials, Boca Raton, FL USA
[4] Gastro One, Germantown, TN USA
[5] Arizona Liver Hlth, Chandler, AZ USA
[6] South Texas Res Inst, Edinburg, TX USA
[7] Axcella Hlth Inc, Cambridge, MA USA
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1694
引用
收藏
页码：1032 / 1033
页数：2
相关论文
共 44 条
  • [21] Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial
    Terauchi, Yasuo
    Tamura, Masahiro
    Senda, Masayuki
    Gunji, Ryoji
    Kaku, Kohei
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1397 - 1407
  • [22] A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) with Mild to Moderate Atopic Dermatitis
    Jacobson, Michael E.
    Myles, Ian A.
    Paller, Amy S.
    Eichenfield, Lawrence F.
    Simpson, Eric Lawrence
    DERMATOLOGY, 2024, 240 (01) : 85 - 94
  • [23] 52-week prospective randomized, doubl-blind placebo-controlled safety and efficacy study of 2 dosages of botulinum toxin type-A treatment for primary axillary hyperhidrosis
    Glaser, DA
    Lowe, NJ
    Eadie, N
    Daggett, S
    Mordaunt, J
    Kowalski, JW
    Brin, MF
    NEUROLOGY, 2004, 62 (07) : A422 - A423
  • [24] Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Mainland China, Taiwan and Hong Kong
    Pan, Changyu
    Han, Ping
    Ji, Qiuhe
    Li, Chengjiang
    Lu, Juming
    Yang, Jinkui
    Li, Wenhui
    Zeng, Jiaoe
    Chan, Julianna
    Hsieh, An-Tsz
    DIABETES, 2013, 62 : A299 - A299
  • [25] Efficacy and safety of canagliflozin rnonotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
    Inagaki, Nobuya
    Kondo, Kazuoki
    Yoshinari, Toru
    Takahashi, Nahoko
    Susuta, Yutaka
    Kuki, Hideki
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (11) : 1501 - 1515
  • [26] Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
    Yuichiro Yamada
    Yasuo Terauchi
    Hirotaka Watada
    Yasuhiko Nakatsuka
    Kazuhito Shiosakai
    Takuo Washio
    Takashi Taguchi
    Advances in Therapy, 2018, 35 : 367 - 381
  • [27] Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
    Yamada, Yuichiro
    Terauchi, Yasuo
    Watada, Hirotaka
    Nakatsuka, Yasuhiko
    Shiosakai, Kazuhito
    Washio, Takuo
    Taguchi, Takashi
    ADVANCES IN THERAPY, 2018, 35 (03) : 367 - 381
  • [28] A Phase 1b, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876, a Novel Fc-FGF-21 Fusion Protein, in Subjects with Type 2 Diabetes Mellitus
    Abuqayyas, Lubna
    Tracy, Michael
    Smith, Shawna
    Anderson, Abraham
    Kaufman, Allegra
    DIABETES, 2017, 66 : A282 - A282
  • [29] Pharmacokinetic, Pharmacodynamic, and Tolerability Profiles of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin: A 4-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study in Japanese Type 2 Diabetes Patients
    Horie, Yoshiharu
    Kanada, Shigeto
    Watada, Hirotaka
    Sarashina, Akiko
    Taniguchi, Atsushi
    Hayashi, Naoyuki
    Graefe-Mody, Eva U.
    Woerle, Hans-Juergen
    Dugi, Klaus A.
    CLINICAL THERAPEUTICS, 2011, 33 (07) : 973 - 989
  • [30] Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
    Saxena, Aditi R.
    Frias, Juan P.
    Gorman, Donal N.
    Lopez, Rene N.
    Andrawis, Nabil
    Tsamandouras, Nikolaos
    Birnbaum, Morris J.
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2805 - 2814
12345